SEC Form 10-K filed by GeneDx Holdings Corp.
$WGS
Retail: Computer Software & Peripheral Equipment
Technology
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2024 | $34.00 | Equal Weight | Wells Fargo |
| 7/10/2024 | $43.00 | Buy | Craig Hallum |
| 6/3/2024 | $21.00 | Hold | Jefferies |
Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More New Executive Leadership Positions Company for Growth and Scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program
Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen
ultraRapid testing addresses the underutilization of testing in the NICU and can lead to more than $15K in healthcare savings per child GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced ultraRapid Whole Genome Sequencing, offering accelerated and comprehensive genomic insights for neonatal and pediatric patients in the NICU and PICU in as soon as 2 days. ultraRapid genome testing delivers a faster diagnosis, providing clinically actionable results and the opportunity to shorten a NICU stay. Genetic diseases are the most common identifiable cause of infant death, and for every baby who fails to receive a genetic diagnosis, thei
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA. Management will participate in a fireside chat on Tuesday, March 4, 2025, at 1:10 p.m. ET. A live and archived webcast of the presentation will be available on the "Events" section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare dis
Wells Fargo initiated coverage of GeneDx with a rating of Equal Weight and set a new price target of $34.00
Craig Hallum initiated coverage of GeneDx with a rating of Buy and set a new price target of $43.00
Jefferies resumed coverage of GeneDx with a rating of Hold and set a new price target of $21.00
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
S-8 POS - GeneDx Holdings Corp. (0001818331) (Filer)
S-8 POS - GeneDx Holdings Corp. (0001818331) (Filer)
S-8 POS - GeneDx Holdings Corp. (0001818331) (Filer)
Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, announced it will release financial results for the fourth quarter 2024 and the full year 2024 before the market opens on Tuesday, February 18, 2025. Management will host a conference call that day to discuss fourth quarter 2024 and full year 2024 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (
Expects to exceed guidance with full year 2024 revenues1 of at least $299 million Expects fourth quarter 2024 revenues1 of at least $92 million Expects to exceed guidance with full year 2024 adjusted gross margin1 of at least 64% Expects fourth quarter 2024 adjusted gross margin1 of at least 68% GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2024. "2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to se
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)